Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Competing Endogenous Rnas Regulatory Crosstalk Networks: The Messages From the Rna World to Signaling Pathways Directing Cancer Stem Cell Development Publisher



Aria H1, 2 ; Azizi M2 ; Nazem S3 ; Mansoori B4 ; Darbeheshti F5 ; Niazmand A6 ; Daraei A7, 8 ; Mansoori Y1, 9
Authors

Source: Heliyon Published:2024


Abstract

Cancer stem cells (CSCs) are one of the cell types that account for cancer heterogeneity. The cancer cells arrest in G0 and generate non-CSC progeny through self-renewal and pluripotency, resulting in tumor recurrence, metastasis, and resistance to chemotherapy. They can stimulate tumor relapse and re-grow a metastatic tumor. So, CSCs is a promising target for eradicating tumors, and developing an anti-CSCs therapy has been considered. In recent years competing endogenous RNA (ceRNA) has emerged as a significant class of post-transcriptional regulators that affect gene expression via competition for microRNA (miRNA) binding. Furthermore, aberrant ceRNA expression is associated with tumor progression. Recent findings show that ceRNA network can cause tumor progression through the effect on CSCs. To overcome therapeutic resistance due to CSCs, we need to improve our current understanding of the mechanisms by which ceRNAs are implicated in CSC-related relapse. Thus, this review was designed to discuss the role of ceRNAs in CSCs' function. Targeting ceRNAs may open the path for new cancer therapeutic targets and can be used in clinical research. © 2024 The Authors
Other Related Docs
7. Endometrial Cancer Stem Cells Related Signaling Pathways, Current Cancer Therapy Reviews (2023)
12. Pseudogenes in Gastric Cancer Pathogenesis: A Review Article, Briefings in Functional Genomics (2017)
17. Long Non-Coding Rnas and Melanoma: From Diagnosis to Therapy, Pathology Research and Practice (2023)
19. Circular Rnas-Mediated Angiogenesis in Human Cancers, Clinical and Translational Oncology (2023)